Top life sciences deals of 2025 signal a bigger capital shift
CURRENT BRIEF VERSION: A new PharmaShots report, produced with data partner DealForma, ranks the top 20 life sciences deals announced in 2025 and points to a year defined by bigger, more strategic transactions across pharma, biotech, and related health sectors. The list itself is broad rather than veterinary-specific, but it lands in the context of a 2025 life sciences market that strengthened across both M&A and capital formation. Deloitte said 193 life sciences transactions totaling $220 billion had been recorded by the end of November 2025, already above 2024’s total deal value, while DealForma reported strong partnership activity early in the year. PharmaShots also highlighted sustained IPO appetite in 2025, with healthcare listings led by Medline Industries’ $7.2 billion raise and followed by companies in diagnostics, medtech, digital health, and AI-enabled care. (linkedin.com)
Why it matters: For veterinary professionals, this kind of dealmaking matters even when companion animal or livestock companies aren’t named directly. Large life sciences transactions can reshape capital flows, R&D priorities, diagnostics, supply chains, and pricing power across adjacent animal health markets. That’s especially relevant in a sector already seeing continued consolidation: PitchBook data compiled in a Q4 2025 pet M&A update showed veterinary care services accounted for eight reported pet-sector deals in the quarter, and AVMA’s 2025 economic report shows long-term growth in corporate business structures across U.S. veterinary practice. The financing backdrop also looks meaningful: Blackstone closed a $6.3 billion life sciences fund at its hard cap in late 2025, underscoring how much institutional capital is still being directed toward drug and medtech platforms. (rlhulett.com)
What to watch: Watch whether 2026 capital continues moving from blockbuster human-health deals, IPOs, and large private funds into animal health, veterinary services, diagnostics, and pet wellness platforms. A proposed roughly €10.9 billion take-private of Recordati by CVC Capital Partners is another sign buyers are still pursuing scaled healthcare assets with specialty and rare-disease exposure. (capstonepartners.com)